Merck: new cholesterol drug meets trial goal.
(CercleFinance.com) - On Tuesday Merck said a study on anacetrapib, a new generation cholesterol-lowering drug, met its primary endpoint by significantly reducing coronary events.
The trial showed that anacetrapib significantly reduced major coronary events compared to placebo in patients at risk for cardiac events who are already receiving an effective diet to reduce elevated low-density lipoprotein cholesterol (LDL-C).
Merck said it is now considering whether to file new drug applications with the US Food and Drug Administration (FDA) and other regulatory bodies.
The results of the study will be presented at the European Society of Cardiology meeting at the end of August.
The study included approximately 30,000 patients at high risk of cardiovascular events for at least 4 years.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The trial showed that anacetrapib significantly reduced major coronary events compared to placebo in patients at risk for cardiac events who are already receiving an effective diet to reduce elevated low-density lipoprotein cholesterol (LDL-C).
Merck said it is now considering whether to file new drug applications with the US Food and Drug Administration (FDA) and other regulatory bodies.
The results of the study will be presented at the European Society of Cardiology meeting at the end of August.
The study included approximately 30,000 patients at high risk of cardiovascular events for at least 4 years.
Copyright (c) 2017 CercleFinance.com. All rights reserved.